Loading stock data…
$10.51-0.10 (-0.94%)
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.
Vir Biotechnology, Inc. in the Healthcare sector is trading at $10.51 with a market capitalization of $1.9B. Wall Street consensus targets $21.00 (9 analysts), implying a +99.8% move over the next 12 months. The stock is currently 12% below its 52-week high of $12.00, remaining 13.9% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $238.94M↑ | -$41,000↓ | $63.76M↑ | -$65,000↓ | $1.03M |
| Gross Profit | $238.94M | — | $63.73M↑ | -$54,000↓ | $1.02M |
| Operating Income | $73.47M↑ | -$132.29M↓ | -$47.92M↑ | -$173.44M↓ | -$118.59M |
| Net Income | $80.08M↑ | -$125.69M↓ | -$42.92M↑ | -$163.14M↓ | -$110.96M |
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of ...